
|Videos|October 17, 2014
Combining Targeted Agents for the Treatment of Lung Cancer
Author(s)Heather Wakelee, MD
Heather Wakelee, MD, associate professor, Stanford University School of Medicine, discusses the need to combine agents for the treatment of lung cancer.
Advertisement
Clinical Pearls
Heather Wakelee, MD, associate professor, Stanford University School of Medicine, discusses the need to combine agents for the treatment of lung cancer.
- It is widely believed that 1 molecularly-targeted agent will not be able to cure lung cancer.
- Long term responses have been observed with 1 targeted agent.
- Research needs to be conducted regarding which combinations of agents will be most beneficial or curative.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Breast Cancer Test Using Proteomic Profiling and AI Demonstrates High Performance
5










































